Why Loblaw’s (TSX:L) Stock Price Fell 3.8% Yesterday

Loblaw’s stock price falls on rising costs, but its leading, defensive business is a good enough reason to own it in this environment.

| More on:
Supermarket aisle with empty green shopping cart

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Loblaw’s (TSX:L) stock price has been having a pretty good 2020 so far. It is up 5.7% year to date and up 18.6% from March lows. Clearly, Loblaw stock has been a solid defensive holding through this rough period.

Yesterday, Loblaw reported first-quarter earnings that were boosted by a March demand surge. Revenue increased 10.8% and earnings surged 30%. So, why was Loblaw’s stock price down yesterday off these results?

Loblaw’s stock price falls on revenue mix changes

Breaking down Loblaw’s results, we can see some trends emerge. Firstly, much of the extraordinary revenue growth occurred in the last two weeks of March. There has been sustained increased buying since then, with less attention to price. This can be expected to continue in the short term. The longer the crisis goes on, however, the more likely we will start seeing greater economic hardship and pricing sensitivity.

Secondly, e-commerce volume increased threefold due to the pandemic. This makes total sense. Given the circumstances, Loblaw has eliminated pick-up fees and lowered delivery fees. Management is unsure how long this will last, but this is a pressure point on margins.

And thirdly, higher-margin product revenue declined significantly as part of customers’ pandemic response. Lower sales of higher-margin categories like general merchandise, apparel, and beauty products will negatively impact margins going forward.

Expect second-quarter, COVID-related costs to hit Loblaw’s stock price

Increased costs related to keeping employees and customers safe will pressure results. Increasing wages and cleaning practices, and the installation of plastic barriers and other safeguards are big investments. According to management, this increased cost structure will persist for at least the next quarter. While visibility is low, we can safely assume that this pressure may remain for the full year. The estimated incremental cost due to the pandemic will be $90 million per month.

This will have a significant negative impact on Loblaw’s earnings.

Loblaw stock is attractive due to its defensiveness

Even with these hits to Loblaw’s financials, Loblaw stock is still attractive. This is due to its involvement in the consumer staples and pharmacy businesses, which will withstand this crisis. This is also due to the fact that Loblaw is in good financial shape. In the first quarter, the company generated $1.1 billion in free cash flow. Lastly, this is due to the fact that Loblaw is Canada’s largest food retailer and leading pharmacy outlet.

Even in this more difficult environment, Loblaw can be expected to maintain its leadership positions. The company has strong private label brands and leading market share in prescriptions and front store sales at Shoppers Drug Mart. This will all continue to work to solidify the company’s value proposition and its free cash flow generation.

Foolish bottom line

Loblaw’s stock price reacted negatively to first-quarter results yesterday. The stock got hit, even though the company is seeing unprecedented, booming demand. If we lift the curtain, we see a lot of pressure on costs and margins. This has left investors with a negative reaction. Now, we have to weigh this margin pressure with other factors. At least Loblaw is open for business, and that is a comparatively good spot in today’s environment.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned.

More on Coronavirus

little girl in pilot costume playing and dreaming of flying over the sky
Coronavirus

Air Canada Stock: How High Could it go?

AC stock is up 29% in the last six months alone, so should we expect more great things? Or is…

Read more »

eat food
Coronavirus

Goodfood Stock Doubles Within Days: Time to Buy?

Goodfood (TSX:FOOD) stock has surged 125% in the last few weeks, so what happened, and should investors hop back on…

Read more »

stock data
Tech Stocks

If I Could Only Buy 1 Stock Before 2023, This Would Be It

This stock is the one company that really doesn't deserve its ultra-low share price, so I'll definitely pick it up…

Read more »

Aircraft Mechanic checking jet engine of the airplane
Coronavirus

Air Canada Stock Fell 5% in November: Is it a Buy Today?

Air Canada (TSX:AC) stock saw remarkable improvements during its last quarter but still dropped 5% with more recession hints. So,…

Read more »

Airport and plane
Coronavirus

Is Air Canada Stock a Buy Today?

Airlines are on the rebound. Does Air Canada stock deserve to be on your buy list?

Read more »

A patient takes medicine out of a daily pill box.
Coronavirus

Retirees: 2 Healthcare Stocks That Could Help Set You up for Life

Healthcare stocks offer an incredible opportunity for growth for those investors who look to the right stocks, such as these…

Read more »

sad concerned deep in thought
Coronavirus

Here’s Why I Just Bought WELL Health Stock

WELL Health stock (TSX:WELL) may be a healthcare stock and a tech stock, but don't let that keep you from…

Read more »

healthcare pharma
Coronavirus

WELL Stock: The Safe Stock Investors Can’t Afford to Ignore

WELL stock (TSX:WELL) fell 68% from peak to trough, and yet there's no good reason as to why. So now…

Read more »